NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TORL BioTherapeutics

TORL BioTherapeutics

Private
Culver City, CaliforniaHealthcare & Life Scienceshttps://torlbio.com/

Last Round

Series C

Oct 7, 2025

Total Funding Raised

$461.9M

Company Overview

TORL BioTherapeutics is a biopharmaceutical company that develops antibody-drug conjugates and monoclonal antibodies for the treatment of various cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugateADConcologymonoclonal antibodybiopharmaceuticalclinical trialssolid tumorsdrug discoverybiotechtargeted therapycancer researchpipeline assetsbiologicsdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TORL BioTherapeutics Comparables

Compare TORL BioTherapeutics with similar companies based on industry and business-model similarity.

TORL BioTherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Gilead Sciences
87%
Sutro Biopharma Inc
80%
Genmab A/S
79%

TORL BioTherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series COct 7, 2025
Series B ExtensionApr 10, 2024
Series BApr 13, 2023

Key People

Founding team and executive leadership

Dave Licata

President And CFO TORL BioTherapeutics Executive Chairman 1200 Pharma

Executive Team

TORL BioTherapeutics Investors

Notable investors and investment history

TORL BioTherapeutics investors
InvestorRounds
RA Capital ManagementSeries B Extension
Vertex Ventures HCSeries B, Series B Extension
Perceptive AdvisorsSeries B, Series B Extension
XontogenySeries B, Series B Extension
TD SecuritiesSeries B
Blue Owl CapitalSeries B, Series B Extension
Deep Track CapitalSeries B, Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2024

    $158M round led by Deep Track Capital.

  • Apr 13, 2023

    $158M round led by Goldman Sachs Asset Management.

TORL BioTherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TORL BioTherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TORL BioTherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCulver City, California
Employee Range65
Year Founded2018
Last FundingOct 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.